Warfarin Sodium

华法林钠

Report date: 2023/03/21 10:39:36
NME

Base Information

Drug NameWarfarin Sodium
Drug Alias Name华法林Warfarinum华法令钠Warfarine硫酸华法林钠 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVitamin K epOxide reductase complex subunit 1 inhibitors
TargetsVitamin K epOxide reductase complex subunit 1
Therapy Area/IndicationsHemorrhageDiabetes Mellitus, Type 2Thrombocytopenia +[17] 
Global Approved IndicationsVenous ThrombosisThromboembolismMyocardial Infarction +[8] 
Approved Indications in ChinaVenous ThrombosisThromboembolismMyocardial Infarction +[5] 
Original Approved Country/TerritoryUnited States
Original Approved Date1954/06/08
Country/TerritoryCanadaUnited StatesTaiwan +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Canada CoTeva Uk LtdQilu Pharmaceutical Co Ltd
Inactive CompaniesBristol Myers Squibb SrlcompanyGlaxosmithkline PlcUniversity Of Rochester +[12] 
Active IndicationsVenous ThrombosisThromboembolismMyocardial Infarction +[10] 
Inactive IndicationsHemorrhageDiabetes Mellitus, Type 2Thrombocytopenia +[7] 

Other Information

ATC CodeB01AA03
Related LinksWikipediaDrugBankKEGG